An atypical case of lung neoplasia

Authors

Keywords:

pulmonary neoplasia, atypical cancer, small cells.

Abstract

Introduction: Lung cancer is considered the malignant tumor that produces more deaths in the world over other cancers and in 90% of cases they are diagnosed in advanced stages.
Objectives: To describe an atypical form of presentation of lung neoplasia.
Clinical case: A 68-year-old male patient, a smoker over 37 years of age, with a history of heart failure for which he was treated with nitrosorbide (10 mg) 1 tablet every 8 hours and aspirin (125 mg) 1 tablet per day. He reported pain in the lower left limb, which was not relieved throughout the day and was exacerbated by physical movements and efforts. In addition, there was an increase in volume in the middle anterior region of the chest, approximately 15 cm long, hard, painful, with regular edges, smooth surface. He had no cough, dyspnea, fever or other symptoms.
Conclusions: The patient had a different form of lung neoplasia presentation. He did not present respiratory manifestations that oriented towards the identification of a pulmonary cause. The identification of the carcinogenic pattern is necessary, as well as its staging to prescribe the appropriate treatment and management.

Downloads

Download data is not yet available.

Author Biographies

Mislay Rodriguez Garcia, Hospital Militar Clinico Quirurgico Docente Doctor Joaquin Castillo Duany.

Especialista en Primer Grado en Medicina General Integral. Especialista en Psiquiatria.

Martha Campos Muñoz, Hospital Militar Clinico Quirurgico Docente Doctor Joaquin Castillo Duany.

 Especialista Segundo Grado Medicina General Integral. Master en APS. Profesor auxiliar. Investigador Agregado.  

Especialista de docencia del Centro de desarrollo del Hospital Militar Clinico Quirurgico  Docente   Doctor Joaquin Castillo Duany.

Daniela De la Caridad Rodriguez Campos, Universidad de Ciencias Medicas. Facultad No.1. Santiago de Cuba, Cuba.

Estudiante de 6to año de medicina.

Osmel Daniel Chacon Reyes, Universidad de Ciencias Medicas. Facultad N0.1. Santiago de Cuba, Cuba.

Estudiante de 6to año de medicina.

Joel Reynaldo Chiang Borges, Universidad de Ciencias Medicas. Facultad No.1.Santiago de Cuba, Cuba.

Estudiante de 6to año de medicina.

References

1. Noya Chaveco ME, Moya González NL. Roca Goderich. Temas de Medicina Interna. Tomo I 5ta ed. La Habana: ECIMED; 2017 [acceso 7/10/2019]. Disponible en: https://bvs.sld.cu/libros_texto/roca_temas_medicina_interna_tomo1_-quintaedicion/cap34.pdf

2. Zimmermann ML, Bahurin A, Innos K. Tendencias divergentes en la incidencia de cáncer de pulmón por género,edad y tipo histológico en Estonia: un estudio nacional basado en la población. BMC Cáncer. 2017 [acceso: 10/11/2018]; 17(1): [aprox. 20 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577806

3. Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. Epidemiología internacional del cáncer de pulmón: últimas tendencias, disparidades y características tumorales. J Thorac Oncol. 2016 [acceso: 4/10/2018]; 11(10): [aprox. 30 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512876

4. Cáceres Lavernia HH, Nenínger Vinageras E. Comportamiento del cáncer de pulmón células pequeñas en el hospital Hermanos Ameijeiras. Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta. 2016 [acceso 7/12/2018]; 41(2): [aprox. 12 p.]. Disponible en: https://revzoilomarinello.sld.cu/index.php/zmv/article/view/630/html_146

5. Ministerio de Salud Pública; Dirección Nacional de Estadísticas y Registros Médicos. Anuario Estadístico de Salud 2016. La Habana: MINSAP; 2016. 2016.

6. Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, et al. Un estudio aleatorizado de fase II de Linsitinib (OSI-906) frente a Topotecán en pacientes con cáncer de pulmón de células pequeñas recurrente. Oncologist. 2016 [acceso 5/9/2018]; 21(10): [aprox. 7 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061534/pdf/theonc-ologist_16220CTR.pdf

7. Liu SY, Wu YL. Ensayos clínicos en curso de los inhibidores PD-1 y PD-L1 para el cáncer de pulmón en China. J Hematol Oncol. 2017 [acceso 5/9/2018];10(1):1-8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499002/pdf/13045_-2017_Article_506.pdf

8. Acosta Reynoso IM, Remón Rodríguez L, Segura Peña R, Ramírez Ramírez G, Carralero Rivas Á. Factores de riesgo en el cáncer de pulmón. CCM. 2016 [acceso 3/1/2019]; 20(1): [aprox. 10 p.]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1560-43812016000100005&lng=es&nrm=iso&tlng=es

9. Pérez Velázquez E, Cárdenas Igarza JA, Reyes Góngora D. Variables clínicas en pacientes con cáncer de pulmón. Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta. 2016 [acceso 5/1/2019]; 41(10): [aprox. 6 p.]. Disponible en: https://revzoilomarinello.sld.cu/index.php/zmv/article/view/947/pdf_348

10. Pérez Guerra LE, Rodríguez Flores O, Morales Morales Y, Amores Ramos A, Jaime Valdés L, Pérez Rodríguez A. Cáncer de pulmón: aspectos clínicos y diagnósticos en pacientes afectados del Policlínico "Marta Abreu". Estudio de cinco años. Acta méd centro. 2017 [acceso 7/12/19]; 11(3):[aprox. 8 p.]. Disponible en: https://www.revactamedicacentro.sld.cu/index.php/amc/article/view/833/1036

11. MedlinePlus. Bethesda (MD): Biblioteca Nacional de Medicina (EE. UU.); [actualizado 11 Dic 2017; acceso 11/12/2019]. Cáncer de pulmón; [aprox. 9 pantallas]. Disponible en: https://medlineplus.gov/spanish/lungcancer.html

12. Barbosa IR, Bernal Pérez MM, Costa ICC, Jerez-Roig J, de Souza DLB. Supervivencia del cáncer de pulmón en pacientes tratados en un hospital de referencia en Zaragoza (España). Semergen. 2016 [acceso 12/12/2018];42(6):380-87. Disponible en: https://www.clinicalkey.es/#!/content/journal/1-s2.0-S113835931500266X

Downloads

Published

2021-01-01

How to Cite

1.
Rodriguez Garcia M, Campos Muñoz M, Rodriguez Campos DD la C, Chacon Reyes OD, Chiang Borges JR. An atypical case of lung neoplasia. Rev Cubana Med Milit [Internet]. 2021 Jan. 1 [cited 2025 Apr. 4];50(1):e0210523. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/523

Issue

Vol. 50 No. 1 (2021): January - March

Section

Case Presentation

License

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.